TrialThe Lancet. Oncology2019

Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial.

Daniel J Khalaf et al.PubMed ↗Publisher ↗

No numbers read from the abstract.